News

– Strengthening Development Structure for Phase III NIPCs Trial and Accelerating Global Expansion –

Human Life CORD Japan Inc. (Head Office: Chuo-ku, Tokyo; President & CEO: Masamitsu Harata; hereinafter “HLC”), a company pioneering the practical application and global deployment of umbilical cord–derived mesenchymal stromal cells (UC-MSCs) as regenerative medicine products, hereby announces the completion of its Series C financing round.

Through the second offering on “FUNDINNO PLUS+” and additional investments from business corporations, HLC has reached a cumulative total funding amount of approximately JPY 1.9 billion in its Series C round and has successfully closed this financing.

Overview of Series C Round (Summary)

• ・Total amount raised (Series C cumulative): Approximately JPY 1.9 billion

 

• ・Key investors / allottees:
  • – ROHTO Pharmaceutical Co., Ltd. (Osaka, Japan)
  • – SRD Holdings Co., Ltd. (Tokyo, Japan)
  • – CafeGroup Inc. (Tokyo, Japan)
  • – Nikko Chemicals Co., Ltd. (Tokyo, Japan)
  • – Company management
  • – 125 qualified investors through FUNDINNO PLUS+
  • – Other business corporations and individual investors

 

• ・Primary use of funds:
  • – Preparation for the Phase III clinical trial for post–hematopoietic stem cell transplantation non-infectious pulmonary complications (NIPCs)
  • – Strengthening of the UC-MSC master cell manufacturing structure
  • – Promotion of a global manufacturing and supply ecosystem for UC-MSCs

Masamitsu Harata, President and CEO of Human Life CORD Japan Inc. commented:

“We understand that this investment reflects not only empathy toward our vision and management philosophy, but also recognition of our steady progress toward the sustainable clinical implementation of UC-MSCs.

We are deeply grateful for the trust placed in us through this important funding, which will allow us to deliver tangible value to society.

We will steadily build the operational framework for the upcoming Phase III clinical trial targeting NIPCs, our lead pipeline.

Building on this foundation, we will further accelerate the construction of a global cell therapy ecosystem, centered on Japan and the United States, and deliver new treatment options to patients around the world.”

 
HLC will further enhance its integrated framework spanning research and development, manufacturing, and business development to deliver the potential of UC-MSCs to society as established medical solutions.
Through close collaboration with partners both in Japan and overseas, we will continue to advance toward a future in which cell therapies become a widely accessible and sustainable therapeutic option.

[Press Release PDF] Human Life CORD Completes Series C Financing, Reaching a Total of JPY 1.9 Billion

 
[Contact for Media Inquiries]
Public Relations, Human Life CORD Japan Inc.
Attn: Yuki Hayashi
TEL: +81-80-4671-0405
Email: info@humanlifecord.com